RARX News and Press, Ra Pharmaceuticals Inc. From 10/10/19

Ra Pharmaceuticals (NASDAQ: RARX )  +102%  on being acquired by UCB SA. More news on: Ra Pharmaceuticals, Inc., OncoSec Medical Incorporated, Bed Bath & Beyond Inc., Stocks on the move, Read more ...

Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab , an FcRn targeting antibody also in phase 3 Will enrich U...

Ra Pharmaceuticals (NASDAQ: RARX ) initiates dosing in the RAISE study, its pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). More news on: Ra Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Top-line data from the Phase 3 RAISE study expected in early 2021 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gM...

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease in which the nerve cells in the spinal cord and brain slowly die, leading to impairment of voluntary muscle movement. Patients lose the ability to eat, breathe, walk, and talk ...

Multi-center platform trial sponsored by the Healey Center will simultaneously assess multiple drug regimens Zilucoplan selected by leading experts in ALS as one of the first therapeutic candidates to be tested Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection o...

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement c...

Marks the second compound from Ra’s Extreme Diversity™ platform to enter clinical trials Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.S. ...

Ra Pharmaceuticals (NASDAQ: RARX ): Q2 GAAP EPS of -$0.52 misses by $0.03 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiation of single, pivotal, 12-week, Phase 3 gMG clinical trial on track for the second half of 2019 Initiation of multi-center, Phase 2 IMNM clinical trial on track for the second half of 2019 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the s...